Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

2.

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.

Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 17;11:1921-8. doi: 10.2147/COPD.S109661. eCollection 2016.

3.

Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.

Bethke TD, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Hauschke D, David M, Lahu G, Zech K, Hermann R, Siegmund W.

Int J Clin Pharmacol Ther. 2006 Nov;44(11):572-9.

PMID:
17176624
4.

Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.

Eckermann G, Lahu G, Nassr N, Bethke TD.

J Clin Pharmacol. 2012 Feb;52(2):251-7. doi: 10.1177/0091270010389467.

PMID:
21257799
5.

The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.

Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Reutter F, Lahu G, Zech K, Bethke TD.

J Clin Pharmacol. 2007 Aug;47(8):1005-13.

PMID:
17660483
6.

Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.

Lahu G, Nassr N, Herzog R, Elmlinger M, Ruth P, Hinder M, Huennemeyer A.

J Clin Pharmacol. 2011 Apr;51(4):586-93. doi: 10.1177/0091270010370590. Epub 2010 May 13.

PMID:
20466871
7.

The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

Böhmer GM, Nassr N, Wenger M, Hünnemeyer A, Lahu G, Templin S, Gleiter CH, Hermann R.

J Clin Pharmacol. 2009 Apr;49(4):389-97. doi: 10.1177/0091270008330980.

PMID:
19318692
8.

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Lahu G, Hünnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, McCracken N, Facius A.

Clin Pharmacokinet. 2010 Sep;49(9):589-606. doi: 10.2165/11536600-000000000-00000.

PMID:
20690782
9.

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Rabe KF.

Br J Pharmacol. 2011 May;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x. Review.

10.

Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.

Lecaillon JB, Kaiser G, Palmisano M, Morgan J, Della Cioppa G.

Eur J Clin Pharmacol. 1999 Apr;55(2):131-8.

PMID:
10335908
11.

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF.

Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13.

PMID:
25684586
12.

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA.

Swiss Med Wkly. 2012 Jul 25;142:w13628. doi: 10.4414/smw.2012.13628. Review.

13.

No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.

Böhmer GM, Gleiter CH, Mörike K, Nassr N, Walz A, Lahu G.

J Clin Pharmacol. 2011 Apr;51(4):594-602. doi: 10.1177/0091270010368282. Epub 2010 May 19.

PMID:
20484614
14.

Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

Hermann R, Nassr N, Lahu G, Péterfai E, Knoerzer D, Herzog R, Zech K, de Mey C.

Clin Pharmacokinet. 2007;46(5):403-16.

PMID:
17465639
15.

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Pinner NA, Hamilton LA, Hughes A.

Clin Ther. 2012 Jan;34(1):56-66. doi: 10.1016/j.clinthera.2011.12.008. Review.

PMID:
22284994
16.

Roflumilast in the management of chronic obstructive pulmonary disease.

Lipari M, Benipal H, Kale-Pradhan P.

Am J Health Syst Pharm. 2013 Dec 1;70(23):2087-95. doi: 10.2146/ajhp130114. Review.

PMID:
24249758
17.

Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.

McCracken N, Lahu G, Bethke TD.

Int J Clin Pharmacol Ther. 2011 Jun;49(6):388-96.

PMID:
21612746
18.

Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Lahu G, Huennemeyer A, Herzog R, McCracken N, Hermann R, Elmlinger M, Zech K.

Int J Clin Pharmacol Ther. 2009 Apr;47(4):236-45.

PMID:
19356389
19.

Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.

Huennemeyer A, Nassr N, Bredenbröker D, Lahu G.

Expert Opin Drug Saf. 2011 Jul;10(4):509-19. doi: 10.1517/14740338.2011.581659. Epub 2011 May 17.

PMID:
21585288
20.

Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.

Bethke TD, Hartmann M, Hünnemeyer A, Lahu G, Gleiter CH.

Int J Clin Pharmacol Ther. 2011 Aug;49(8):491-9.

PMID:
21781649

Supplemental Content

Support Center